Literature DB >> 28927778

Introducing nerve-sparing approach during minimally invasive radical hysterectomy for locally-advanced cervical cancer: A multi-institutional experience.

Francesco Raspagliesi1, Giorgio Bogani2, Arsenio Spinillo3, Antonino Ditto1, Stefano Bogliolo3, Jvan Casarin4, Umberto Leone Roberti Maggiore5, Fabio Martinelli1, Mauro Signorelli1, Barbara Gardella3, Valentina Chiappa1, Cono Scaffa1, Simone Ferrero6, Antonella Cromi4, Domenica Lorusso1, Fabio Ghezzi4.   

Abstract

OBJECTIVE: To evaluate the impact of nerve-sparing (NS) approach on outcomes of patients undergoing minimally invasive radical hysterectomy (MRH) for locally advanced stage cervical cancer (LACC).
METHODS: Data of consecutive patients undergoing minimally invasive surgery for LACC were retrospectively retrieved in a multi-institutional setting from 2009 to 2016. All patients included had minimally invasive class III radical hysterectomy (MRH or NS-MRH). Propensity matching algorithm was used to decrease possible allocation bias when comparing outcomes between groups.
RESULTS: Overall, 83 patients were included. The prevalence of patients undergoing NS approach increased aver the study period (from 7% in the year 2009-2010 to 97% in the year 2015-2016; p-for-trend < 0.001). NS-MRH and MRH were performed in 47 (57%) and 36 (43%) patients, respectively. After the application the propensity-matching algorithm, we compared 35 patients' pair (total 70 patients). Postoperative complications rate was similar between groups. Patients undergoing NS-LRH experienced shorter hospital stay than patients undergoing LRH (3.6 vs. 5.0 days). 60-day pelvic floor dysfunction rates, including voiding, fecal and sexual alterations, were lower in the NS group in comparison to control group (p = 0.02). Five-year disease-free (p = 0.77) and overall (p = 0.36) survivals were similar comparing NS-MRH with MRH.
CONCLUSIONS: The implementation of NS approach in the setting of LACC improves patients' outcomes, minimizing pelvic dysfunction rates. NS approach has not detrimental effects on survival outcomes.
Copyright © 2017 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights reserved.

Entities:  

Keywords:  Cervical cancer; Laparoscopy; Neoadjuvant chemotherapy; Nerve sparing; Robotic

Mesh:

Year:  2017        PMID: 28927778     DOI: 10.1016/j.ejso.2017.08.015

Source DB:  PubMed          Journal:  Eur J Surg Oncol        ISSN: 0748-7983            Impact factor:   4.424


  5 in total

Review 1.  Nerve-sparing radical hysterectomy compared to standard radical hysterectomy for women with early stage cervical cancer (stage Ia2 to IIa).

Authors:  Chumnan Kietpeerakool; Apiwat Aue-Aungkul; Khadra Galaal; Chetta Ngamjarus; Pisake Lumbiganon
Journal:  Cochrane Database Syst Rev       Date:  2019-02-12

Review 2.  Voiding Dysfunction After Non-urologic Pelvic Surgery.

Authors:  Felix Cheung; Jaspreet S Sandhu
Journal:  Curr Urol Rep       Date:  2018-08-06       Impact factor: 3.092

3.  Minimally invasive surgery improves short-term outcomes of nerve-sparing radical hysterectomy in patients with cervical cancer: a propensity-matched analysis with open abdominal surgery.

Authors:  Giorgio Bogani; Diego Rossetti; Antonino Ditto; Fabio Martinelli; Valentina Chiappa; Chiara Leone; Umberto Leone Roberti Maggiore; Domenica Lorusso; Francesco Raspagliesi
Journal:  J Gynecol Oncol       Date:  2018-11-27       Impact factor: 4.401

4.  Radical Hysterectomy After Neoadjuvant Chemotherapy for Locally Bulky-Size Cervical Cancer: A Retrospective Comparative Analysis between the Robotic and Abdominal Approaches.

Authors:  Chia-Hao Liu; Yu-Chieh Lee; Jeff Chien-Fu Lin; I-San Chan; Na-Rong Lee; Wen-Hsun Chang; Wei-Min Liu; Peng-Hui Wang
Journal:  Int J Environ Res Public Health       Date:  2019-10-11       Impact factor: 3.390

5.  Surgical, Urinary, and Survival Outcomes of Nerve-sparing Versus Traditional Radical Hysterectomy: A Retrospective Cohort Study in China.

Authors:  Lei Li; Shuiqing Ma; Xianjie Tan; Sen Zhong; Ming Wu
Journal:  Am J Clin Oncol       Date:  2019-10       Impact factor: 2.339

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.